Mendus – executive interview

In this video, we speak with Dr Tariq Mughal, chief medical officer at Mendus. We discuss Tariq’s interest in the blood cancer space before moving on to Mendus’s lead programme in acute myeloid leukaemia (AML) maintenance, as well as the potential to expand vididencel’s application to other indications.

Mendus is a Sweden-based immuno-oncology company specialised in allogeneic dendritic cell biology. Its leading clinical candidate is vididencel, an off-the-shelf cell-based cancer vaccine, which is being evaluated in clinical trials as a potential maintenance treatment for acute myeloid leukaemia (AML, the lead programme) and ovarian cancer. In AML, vididencel has shown clinical proof of conceptas a single-agent maintenance therapy in the ADVANCE II trial, and it is currently being evaluated in the Phase II CADENCE trial (sponsored and conducted by the Australasian Leukaemia and Lymphoma Group) in combination with Onureg. In parallel, Mendus is gearing up for the pivotal stages of development, and is on track to be pivotal-stage ready from H225.